Assorted News from the Last Week: AWS is providing $10 million to accelerate research for pediatric health care and to better understand rare diseases, including
Assorted News from the Last Week: CAC2 Supporting Organization Member Day One Biopharmaceuticals announced it has entered into an exclusive licensing agreement with MabCare Therapeutics
Assorted News from the Last Week: Bristol Myers Squibb’s Augtyro (repotrectinib) has secured an accelerated approval from the FDA for the treatment of adult and
Assorted News from the Last Week: Research from the University of Birmingham could pave the way for using MRI scanning combined with machine learning to
Assorted News from the Last Week: The FDA granted accelerated approval to Eli Lilly And Co’s selpercatinib (Retevmo) for pediatric patients two years of age and
Assorted News from the Last Week: The FDA Pediatric ODAC met to “discuss perspectives on the impact of FDARA on the field of pediatric oncology,
Assorted News from the Last Week: St. Jude survivorship portal and its ability to facilitate breakthroughs in pediatric cancer survivorship research were published recently in Cancer
Assorted News from the Last Week: To understand how CNS tumors impact the AYA population, NCI-CONNECT (Comprehensive Oncology Network Evaluating Rare CNS Tumors), the Central
Assorted News from the Last Week: Brain cancer in children is notoriously hard to treat – a new mRNA cancer vaccine triggers an attack from
Assorted News from the Last Week: Congratulations to CAC2 Supporting Organization Day One Biopharmaceuticals. The FDA has granted accelerated approval to tovorafenib (Ojemda) for the
